CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making
Authors
Keywords
-
Journal
Scientific Reports
Volume 8, Issue 1, Pages -
Publisher
Springer Nature America, Inc
Online
2018-09-20
DOI
10.1038/s41598-018-32569-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma
- (2018) Johannes Breyer et al. Clinical Genitourinary Cancer
- Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset
- (2017) Woonyoung Choi et al. EUROPEAN UROLOGY
- Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification
- (2017) Gottfrid Sjödahl et al. JOURNAL OF PATHOLOGY
- Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer
- (2016) MAXIMILIAN CHRISTIAN KRIEGMAIR et al. ANTICANCER RESEARCH
- Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
- (2016) Jakob Hedegaard et al. CANCER CELL
- A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157
- (2016) Noah M. Hahn et al. CLINICAL CANCER RESEARCH
- Molecular Signature of Response to Pazopanib Salvage Therapy for Urothelial Carcinoma
- (2016) Patrizia Pinciroli et al. Clinical Genitourinary Cancer
- Molecular Biomarkers in Bladder Cancer: Novel Potential Indicators of Prognosis and Treatment Outcomes
- (2016) Masayoshi Nagata et al. DISEASE MARKERS
- Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role ofCDKN2Adeletions in theFGFR3pathway
- (2016) Michelle R Downes et al. HISTOPATHOLOGY
- Biomarkers for precision medicine in bladder cancer
- (2016) Takahiro Kojima et al. International Journal of Clinical Oncology
- Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use
- (2016) Harshnira Patani et al. Oncotarget
- Emerging therapeutic targets in bladder cancer
- (2015) Benedito A. Carneiro et al. CANCER TREATMENT REVIEWS
- Genetic subtypes of invasive bladder cancer
- (2015) David J. McConkey et al. CURRENT OPINION IN UROLOGY
- Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification
- (2015) Norma Palma et al. EUROPEAN UROLOGY
- Complexity of FGFR signalling in metastatic urothelial cancer
- (2015) Alejo Rodriguez-Vida et al. Journal of Hematology & Oncology
- Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
- (2014) Woonyoung Choi et al. CANCER CELL
- Toward a Molecular Pathologic Classification of Urothelial Carcinoma
- (2013) Gottfrid Sjödahl et al. AMERICAN JOURNAL OF PATHOLOGY
- A Phase II Safety and Efficacy Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic Urothelial Cancer
- (2013) Roberto Pili et al. Clinical Genitourinary Cancer
- RB1 in cancer: Different mechanisms of RB1 inactivation and alterations of pRb pathway in tumorigenesis
- (2013) Riccardo Di Fiore et al. JOURNAL OF CELLULAR PHYSIOLOGY
- Fibroblast Growth Factor Receptors-1 and -3 Play Distinct Roles in the Regulation of Bladder Cancer Growth and Metastasis: Implications for Therapeutic Targeting
- (2013) Tiewei Cheng et al. PLoS One
- CDKN2A homozygous deletion is associated with muscle invasion in FGFR3-mutated urothelial bladder carcinoma
- (2012) Sandra Rebouissou et al. JOURNAL OF PATHOLOGY
- Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance
- (2012) V Chell et al. ONCOGENE
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Cellular senescence and tumor suppressor gene p16
- (2011) Hani Rayess et al. INTERNATIONAL JOURNAL OF CANCER
- Expression ratio of CCND1 to CDKN2A mRNA predicts RB1 status of cultured cancer cell lines and clinical tumor samples
- (2011) Shinji Mizuarai et al. Molecular Cancer
- Pazopanib Synergizes with Docetaxel in the Treatment of Bladder Cancer Cells
- (2011) Yuan Li et al. UROLOGY
- Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience
- (2010) Faysal A. Yafi et al. BJU INTERNATIONAL
- Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo
- (2010) F R Lamont et al. BRITISH JOURNAL OF CANCER
- Combined Gene Expression and Genomic Profiling Define Two Intrinsic Molecular Subtypes of Urothelial Carcinoma and Gene Signatures for Molecular Grading and Outcome
- (2010) David Lindgren et al. CANCER RESEARCH
- Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression
- (2010) David J. McConkey et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started